The Scottish Medicines Consortium has followed the lead of its equivalent south of the border and decided not to back the use of Pfizer's inhaled insulin product Exubera on Scotland's National Health Service.
Pfizer launched Exubera across the UK last month, even though the National Institute of health and Clinical Excellence, which decides on the cost-effectiveness of new treatments in England and Wales, said it should only be used in diabetes patients with needle phobia or persistent infections from repeated injections.
The SMC said it could not back use of Exubera because Pfizer had not supplied sufficient economic data to enable it to decide on the cost-effectiveness of the product when used as an alternative to injectable insulin.
Source: PharmaTimes
No comments:
Post a Comment